ATE504570T1 - Tartratsalz aus isofagomin und verwendungsverfahren dafür - Google Patents

Tartratsalz aus isofagomin und verwendungsverfahren dafür

Info

Publication number
ATE504570T1
ATE504570T1 AT07252109T AT07252109T ATE504570T1 AT E504570 T1 ATE504570 T1 AT E504570T1 AT 07252109 T AT07252109 T AT 07252109T AT 07252109 T AT07252109 T AT 07252109T AT E504570 T1 ATE504570 T1 AT E504570T1
Authority
AT
Austria
Prior art keywords
isofagomin
salt
tartrate salt
gaucher disease
isofagomine tartrate
Prior art date
Application number
AT07252109T
Other languages
German (de)
English (en)
Inventor
Benjamin Mugrage
David Palling
Kamlesh A Sheth
Philip J Rybczynski
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of ATE504570T1 publication Critical patent/ATE504570T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
AT07252109T 2006-05-24 2007-05-23 Tartratsalz aus isofagomin und verwendungsverfahren dafür ATE504570T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80802006P 2006-05-24 2006-05-24
US89071907P 2007-02-20 2007-02-20

Publications (1)

Publication Number Publication Date
ATE504570T1 true ATE504570T1 (de) 2011-04-15

Family

ID=38462442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07252109T ATE504570T1 (de) 2006-05-24 2007-05-23 Tartratsalz aus isofagomin und verwendungsverfahren dafür

Country Status (14)

Country Link
US (2) US7501439B2 (enExample)
EP (1) EP1860101B1 (enExample)
JP (1) JP5292605B2 (enExample)
AT (1) ATE504570T1 (enExample)
AU (1) AU2007202359B2 (enExample)
BR (1) BRPI0706114A2 (enExample)
CA (1) CA2590122C (enExample)
DE (1) DE602007013648D1 (enExample)
DK (1) DK1860101T3 (enExample)
IL (1) IL183415A (enExample)
MX (1) MX2007006175A (enExample)
PL (1) PL1860101T3 (enExample)
PT (1) PT1860101E (enExample)
WO (1) WO2007140212A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
BRPI0713442A2 (pt) 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
WO2008144773A1 (en) 2007-05-22 2008-11-27 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2009314447A1 (en) * 2008-11-14 2010-05-20 Neuraltus Pharmaceuticals, Inc. Compositions and methods for the treatment of altered alpha-synuclein function
CN109172813B (zh) 2009-07-28 2022-09-02 武田药品工业株式会社 用于治疗戈谢病的组合物和方法
RU2608520C2 (ru) * 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
LT2490532T (lt) 2009-10-19 2017-03-27 Amicus Therapeutics, Inc. Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
AU2013202368B2 (en) 2012-01-25 2016-06-16 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
AU2013225816B2 (en) 2012-03-02 2017-10-26 Takeda Pharmaceutical Company Limited Compositions and methods for treating Type III Gaucher Disease
ES2924829T3 (es) 2012-03-27 2022-10-11 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central
JP2015512913A (ja) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
DE102017103346A1 (de) * 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
CN111278439A (zh) * 2017-10-26 2020-06-12 夏尔人类遗传性治疗公司 包含葡萄糖脑苷脂酶和异烟肼的调配物
MX2020014082A (es) 2018-06-27 2021-04-13 Proteostasis Therapeutics Inc Compuestos que mejoran la actividad del proteasoma.
JP7551087B2 (ja) 2018-06-27 2024-09-17 キネタ, インコーポレイテッド プロテアソーム活性増強化合物
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP7642561B2 (ja) * 2019-04-25 2025-03-10 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A

Also Published As

Publication number Publication date
US20070281975A1 (en) 2007-12-06
EP1860101B1 (en) 2011-04-06
WO2007140212A2 (en) 2007-12-06
JP5292605B2 (ja) 2013-09-18
AU2007202359B2 (en) 2012-02-16
IL183415A0 (en) 2007-09-20
US7863453B2 (en) 2011-01-04
CA2590122A1 (en) 2007-11-24
BRPI0706114A2 (pt) 2008-11-18
US20090176830A1 (en) 2009-07-09
DE602007013648D1 (de) 2011-05-19
CA2590122C (en) 2015-03-31
MX2007006175A (es) 2009-02-16
US7501439B2 (en) 2009-03-10
PT1860101E (pt) 2011-07-12
EP1860101A1 (en) 2007-11-28
JP2007314540A (ja) 2007-12-06
IL183415A (en) 2012-03-29
DK1860101T3 (da) 2011-07-25
PL1860101T3 (pl) 2011-10-31
WO2007140212A3 (en) 2008-12-24
AU2007202359A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
ATE504570T1 (de) Tartratsalz aus isofagomin und verwendungsverfahren dafür
ATE530519T1 (de) Cyclobutylaminderivate
MX350898B (es) Sal de malato de n(4-{[6,7-bis(metiloxi) quinolin-4-il]oxi}fenil)- n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
NO20070470L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
NZ599343A (en) Substituted piperidines that increase p53 activity and the uses thereof
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
PL1960379T3 (pl) Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów
ATE441632T1 (de) Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DE602006013271D1 (de) Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
DE502006003194D1 (de) Salze substituierter allophansäureester und deren verwendung in arzneimitteln
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
DE60331654D1 (de) Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
DE602006008788D1 (de) Verbindungen
ATE546159T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff
EP2023725A4 (en) PESTICIDAL COMPOSITIONS FOR ANTI-ARTHROPOD TREATMENT AND METHODS OF APPLICATION THEREOF
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien
ATE490247T1 (de) Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1860101

Country of ref document: EP